Precise determination of primary cytogenetic abnormalities provides added value for stratification of chronic lymphocytic leukemia patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F19%3A10376963" target="_blank" >RIV/00669806:_____/19:10376963 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/19:10376963

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ESC.bYtNxt" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ESC.bYtNxt</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2018_180201N71" target="_blank" >10.4149/neo_2018_180201N71</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Precise determination of primary cytogenetic abnormalities provides added value for stratification of chronic lymphocytic leukemia patients

Popis výsledku v původním jazyce

Cytogenetic analysis has become a standard procedure in the management of newly diagnosed chronic lymphocytic leukemia patients. Prognostic information is reported based on the presence of certain abnormalities and karyotype complexity after conventional karyotyping and/or fluorescence in situ hybridization (FISH). The information on cytogenetic abnormalities occurring in isolation is robust; however, the performance of patients with two or more cytogenetic abnormalities is heterogeneous and information is scarce. This retrospective study analyzed whether information on the precise determination of primary cytogenetic abnormalities can have some added value in terms of risk stratification in chronic lymphocytic leukemia (CLL) patients. The study cohort was 121 patients without the need to start treatment for CLL immediately after diagnosis but had completed initial cytogenetic analysis. Results from conventional karyotyping after stimulation of CLL cells and FISH analysis were combined. Risk stratification based purely on the determination of primary cytogenetic abnormalities was effective in CLL patients, with comparable results in stratification based on the presence of certain abnormalities and karyotype complexity. It is recommended that information on suspected primary abnormalities is included in cytogenetic reports, especially in patients with two or more abnormalities, because this can provide valuable additional information.

Název v anglickém jazyce

Precise determination of primary cytogenetic abnormalities provides added value for stratification of chronic lymphocytic leukemia patients

Popis výsledku anglicky

Cytogenetic analysis has become a standard procedure in the management of newly diagnosed chronic lymphocytic leukemia patients. Prognostic information is reported based on the presence of certain abnormalities and karyotype complexity after conventional karyotyping and/or fluorescence in situ hybridization (FISH). The information on cytogenetic abnormalities occurring in isolation is robust; however, the performance of patients with two or more cytogenetic abnormalities is heterogeneous and information is scarce. This retrospective study analyzed whether information on the precise determination of primary cytogenetic abnormalities can have some added value in terms of risk stratification in chronic lymphocytic leukemia (CLL) patients. The study cohort was 121 patients without the need to start treatment for CLL immediately after diagnosis but had completed initial cytogenetic analysis. Results from conventional karyotyping after stimulation of CLL cells and FISH analysis were combined. Risk stratification based purely on the determination of primary cytogenetic abnormalities was effective in CLL patients, with comparable results in stratification based on the presence of certain abnormalities and karyotype complexity. It is recommended that information on suspected primary abnormalities is included in cytogenetic reports, especially in patients with two or more abnormalities, because this can provide valuable additional information.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10600 - Biological sciences

Projekt

<a href="/cs/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

—

Svazek periodika

66

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

12

Strana od-do

128-139

Kód UT WoS článku

000465159200016

EID výsledku v databázi Scopus

2-s2.0-85060539955